Recurrent Mantle Cell Lymphoma Clinical Trials in Houston
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
M
Terminated
- Central Nervous System Lymphoma
- +6 more
- Akt/ERK Inhibitor ONC201
- +2 more
- Houston, TexasM D Anderson Cancer Center
2022-03-30
Mar 30, 2022M
Withdrawn
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Houston, TexasM D Anderson Cancer Center
2022-02-23
Feb 23, 2022M
Active, not recruiting
- CCND1 Positive
- +6 more
- Ibrutinib
- +2 more
- Houston, TexasM D Anderson Cancer Center
2022-01-11
Jan 11, 2022V
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Active, not recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
- Ibrutinib
- Laboratory Biomarker Analysis
- Birmingham, Alabama
- +4 more
2021-11-09
Nov 9, 2021M
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Low Dose Radiation Therapy
- Houston, TexasM D Anderson Cancer Center
2021-10-01
Oct 1, 2021M
Terminated
- B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged
- +16 more
- Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells
- +2 more
- Houston, TexasM D Anderson Cancer Center
2021-05-28
May 28, 2021M
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Biospecimen Collection
- Follow-Up
- Houston, TexasM D Anderson Cancer Center
2021-04-30
Apr 30, 2021M
Recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +8 more
- Houston, TexasM D Anderson Cancer Center
2021-02-21
Feb 21, 2021N
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +35 more
- Akt inhibitor MK2206
- laboratory biomarker analysis
- Houston, TexasM D Anderson Cancer Center
2020-10-14
Oct 14, 2020M
Unknown status
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Best Practice
- +3 more
- Houston, TexasM D Anderson Cancer Center
2020-03-23
Mar 23, 2020M
Recruiting
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Ixazomib
- +2 more
- Houston, TexasM D Anderson Cancer Center
2020-01-31
Jan 31, 2020N
Completed
- MYC Positive
- +16 more
- Alisertib
- +2 more
- Houston, TexasM D Anderson Cancer Center
2019-01-25
Jan 25, 2019M
Completed
- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- +45 more
- anti-endosialin/TEM1 monoclonal antibody MORAb-004
- +2 more
- Birmingham, Alabama
- +19 more
2016-01-07
Jan 7, 2016N
Completed
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- +16 more
- recombinant interleukin-12
- laboratory biomarker analysis
- Houston, TexasM D Anderson Cancer Center
2015-04-14
Apr 14, 2015N
Completed
- Anaplastic Large Cell Lymphoma
- +2 more
- Houston, TexasM D Anderson Cancer Center
2014-05-21
May 21, 2014N
Completed
- Cutaneous B-cell Non-Hodgkin Lymphoma
- +20 more
- oblimersen sodium
- +2 more
- Houston, TexasM D Anderson Cancer Center
2014-05-13
May 13, 2014N
Completed
- Anaplastic Large Cell Lymphoma
- +5 more
- Chicago, Illinois
- +1 more
2014-05-07
May 7, 2014N
Terminated
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Mantle Cell Lymphoma
- Houston, TexasM D Anderson Cancer Center
2014-05-02
May 2, 2014N
Completed
- Accelerated Phase Chronic Myelogenous Leukemia
- +50 more
- Akt inhibitor MK2206
- +2 more
- Birmingham, Alabama
- +24 more
2014-04-28
Apr 28, 2014N
Completed
- Adult Grade III Lymphomatoid Granulomatosis
- +61 more
- bevacizumab
- cediranib maleate
- Houston, TexasM D Anderson Cancer Center
2014-02-14
Feb 14, 2014B
Withdrawn
- Contiguous Stage II Mantle Cell Lymphoma
- +4 more
- antineoplaston A10
- +7 more
- Houston, TexasBurzynski Clinic
2013-07-09
Jul 9, 2013N
Completed
- Angioimmunoblastic T-cell Lymphoma
- +16 more
- Houston, TexasM D Anderson Cancer Center
2013-01-22
Jan 22, 2013